[{"orgOrder":0,"company":"Royalty Pharma","sponsor":"PTC Therapeutics","pharmaFlowCategory":"D","amount":"$650.0 million","upfrontCash":"$650.0 million","newsHeadline":"Royalty Pharma Acquires Royalty Interest in Risdiplam From PTC Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","amount":"$450.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biohaven and Royalty Pharma Announce Funding Agreement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","amount":"$650.0 million","upfrontCash":"$575.0 million","newsHeadline":"Royalty Pharma Acquires Additional Royalty Interest from the Cystic Fibrosis Foundation","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"D","amount":"$325.0 million","upfrontCash":"$125.0 million","newsHeadline":"BioCryst Announces $325 Million of Funding from Royalty Pharma and Athyrium Capital Management","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Minerva Neurosciences","pharmaFlowCategory":"D","amount":"$155.0 million","upfrontCash":"$60.0 million","newsHeadline":"Minerva Neurosciences and Royalty Pharma Announce Sale of Seltorexant Royalty for up to $155 Million","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$392.0 million","upfrontCash":"$342.0 million","newsHeadline":"Royalty Pharma Acquires Royalty Interest in Cabozantinib from GSK","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Dicerna Pharmaceuticals","pharmaFlowCategory":"D","amount":"$240.0 million","upfrontCash":"$180.0 million","newsHeadline":"Royalty Pharma Acquires Oxlumo\u2122 Royalty Interest from Dicerna for up to $240 Million","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"MorphoSys","pharmaFlowCategory":"D","amount":"$2,025.0 million","upfrontCash":"$1,425.0 million","newsHeadline":"MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Cytokinetics","pharmaFlowCategory":"D","amount":"$450.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cytokinetics and Royalty Pharma Announce Funding Agreements Totaling up to $450 Million","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Blueprint Medicines","pharmaFlowCategory":"D","amount":"$340.0 million","upfrontCash":"$175.0 million","newsHeadline":"Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Arrowhead Pharmaceuticals","pharmaFlowCategory":"D","amount":"$410.0 million","upfrontCash":"$250.0 million","newsHeadline":"Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,125.0 million","upfrontCash":"$500.0 million","newsHeadline":"Ionis and Royalty Pharma Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis' Genetic Medicines and Commercial Readiness","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Theravance Biopharma","pharmaFlowCategory":"D","amount":"$1,550.0 million","upfrontCash":"$1,100.0 million","newsHeadline":"Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billion in Upfront Cash with Over $1.5 Billion in Potential Total Value","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$475.0 million","upfrontCash":"Undisclosed","newsHeadline":"Royalty Pharma Nabs $475M Milestone from Pfizer upon Migraine Nasal Spray","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Karuna Therapeutics","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"$100.0 million","newsHeadline":"PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"$300.0 million","newsHeadline":"Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin\u00ae (nadofaragene firadenovec-vncg)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Ascendis Pharma","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"PTC Therapeutics","pharmaFlowCategory":"D","amount":"$1,500.0 million","upfrontCash":"$1,000.0 million","newsHeadline":"PTC Therapeutics Announces Evrysdi\u00ae Royalty Agreement with Royalty Pharma for Up To $1.5 Billion","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Arrowhead Pharmaceuticals","pharmaFlowCategory":"D","amount":"$410.0 million","upfrontCash":"$250.0 million","newsHeadline":"Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by Royalty Pharma
Through the license agreement, Royalty Pharma will utilize the investigational product AMG 890 (olpasiran), currently undergoing evaluation in early-stage clinical trials, for treating elevated lipoprotein(a).
The collaboration aims to accelerate the clinical research program for Teva’s TEV-‘749 (olanzapine), a once-monthly subcutaneous long-acting injection of the atypical antipsychotic olanzapine that is currently in Phase 3 for the treatment of schizophrenia.
Under the agreement, Royalty Pharma acquires additional royalties on Evrysdi (risdiplam), a survival motor neuron 2 splicing modifier designed to treat SMA caused by mutations in chromosome 5q that lead to survival motor neuron protein deficiency.
The proceeds will support continued development and commercialization of Endocrine Rare Disease products, including SKYTROFA (lonapegsomatropin-tcgd), a prodrug of somatropin, administered once weekly, and designed to provide sustained release of active, unmodified somatropin.
Under the agreement, Royalty Pharma is acquiring a 5.1 percentage royalty on net sales of Adstiladrin (nadofaragene firadenovec-vncg), a gene therapy developed as a treatment for adult patients with BCG-unresponsive NMIBC, in the United States.
Under the agreement, Royalty Pharma will acquire PureTech’s royalty in Karuna’s KarXT (xanomeline), an oral, investigational M1/M4-preferring muscarinic agonist for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer.
Pfizer has given Royalty Pharma an accelerated milestone payment following the US approval of its migraine nasal spray, Zavzpret (zavegepant). Zavzpret was approved by the U.S. FDA, which provides another important new treatment option for migraine patients.
Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
AMG 890 (olpasiran) is a siRNA originally developed by Arrowhead using its proprietary Targeted RNAi Molecule, or TRiM™, platform. It is designed to lower levels of lipoprotein(a) (Lp(a)), a genetically-determined independent risk factor for cardiovascular disease.
The Company now anticipates it will approach breakeven cash flow in the second half of 2022 without the cash flows from its interest in GSK's Trelegy Ellipta (fluticasone furoate) royalties, driven by disciplined spending within R&D and the growth of YUPELRI®.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
